All articles tagged with #mri contrast agent
A study highlights that MRI contrast agents containing gadolinium can cause harmful metal buildup in some patients, raising concerns about safety and long-term effects, especially given the lack of FDA-approved antidotes for gadolinium retention. The discussion emphasizes the importance of informed consent, understanding risks, and the need for further research into the safety of these agents.
A Phase 3 clinical trial will test a new gadolinium-based MRI contrast agent, gadoquatrane, which uses a dose that is 60% lower than other agents, potentially addressing concerns about kidney problems. Research suggests that myelin-coated nerves may be more vulnerable to inflammatory damage than uncoated ones, opening new avenues for multiple sclerosis (MS) treatment. A study recommends starting MS treatment with high-efficacy disease-modifying therapies (DMTs) to achieve better outcomes, challenging the practice of prescribing less-effective DMTs as first-line treatments.